Subject search results
You have found 59 entries. Starting with the most recently added or updated entries, the list shows in orange the type of entry, year the original document was published (or if one of our own documents, the year last updated), and the type of file you will download when you click on the title. In blue is the document’s title followed by a brief description.
Click blue titles to view full text in a new window Use the selectors at the bottom to turn to the next page in the list of documents Re-order the list by the main topic addressed or by the most recently published documents
If you have not found what you want you could: Tab back to the Subject search page/tab to amend your original search. Try a new search (clears your previous selection). Instead try a free text search for documents which contain the words you specify.
Or try browsing back issues of the magazine or the more recent email bulletins.
Try the information services provided by partner agencies.
Tried everything? E-mail the Findings editor for help by clicking on this logo 
REVIEW 2013 HTM file
Maintenance agonist treatments for opiate dependent pregnant women
Is it better to prescribe pregnant opioid-dependent women methadone, buprenorphine or oral morphine? Just four randomised trials have addressed this issue and their findings are inconclusive, suggesting greater holding power for methadone but less severe neonatal withdrawal with buprenorphine.
STUDY 2019 HTM file
Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder
Can a limited period of being prescribed opiate-type medications generate longer term reductions in the criminal behaviour of patients dependent on illegal opiates like heroin? And of the two main medications – buprenorphine and methadone – which performs best? It seems a key factor is how well they retain patients in treatment.
STUDY 2020 HTM file
Comparative effectiveness of different treatment pathways for opioid use disorder
How do different pathways for the treatment of problem opioid use compare under real-world conditions? For US patients with health insurance, opioid substitution therapy was associated with the greatest risk reduction. However, its protective effect may not be fully realised while federal and insurance plan restrictions continue to limit access to this treatment option.
STUDY 2019 HTM file
Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic
In the Canadian province of British Columbia there was a rapid rise in overdose deaths from 2015, leading to the declaration of a public health emergency in 2016. The response rested on three key interventions: take-home naloxone, opioid substitution therapy, and drug consumption rooms. The province’s highly detailed surveillance data offered an opportunity to estimate their collective and individual impacts on opioid overdose deaths.
Instead of a set programme, a clinic in London tried offering methadone or buprenorphine patients still using heroin or cocaine a selection from a suite of well-supported psychological interventions tailored to the patient and then systematically re-tailored in the light of how they responded. It worked – but did it work well enough, and would the findings be replicated in more typical circumstances?
REVIEW 2017 HTM file
Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies
Opioid substitution therapy is a safe and effective approach for suppressing illicit opioid use. Helping to guide optimal provision, this review investigates the relative effects of methadone and buprenorphine on the rate of mortality over time.
REVIEW 2016 HTM file
Buprenorphine versus methadone for opioid dependence in pregnancy
Among pregnant women, substitute prescribing is preferable to continued illicit opioid use and supervised withdrawal. Buprenorphine has different properties to the dominant treatment option methadone, but both stand to improve pregnancy and infant outcomes.
DOCUMENT 2018 HTM file
Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families: Treatment Improvement Protocol: TIP 63
Expanding access to medication is an important public health strategy for tackling opioid use disorder, concludes US government agency guidelines. While some people stop using opioids without medication, many benefit from access to methadone, naltrexone, and buprenorphine for varying lengths of time, including lifelong treatment.
STUDY 2018 HTM file
The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom
Buprenorphine may be associated with a lower risk of mortality than methadone among people engaged in opioid substitution treatment – but is the pattern of short treatment duration in the UK preventing maximal impact at a population level?
MATRIX CELL 2018 HTM file
Drug Treatment Matrix cell B3: Practitioners; Medical treatment
Seminal and key research and reviews on the influence of the practitioner in the medical treatment of drug dependence. Investigates the how clinician-patient relationships might be affected by enforcing clinic rules and the potential importance of doctors forming a “whole person’ relationship with patients.
Select search results page
NEXT
1 2 3 4 5 6